CN101015680B - Use of F-Glucoside peptide in preparing medicine for treating tumour - Google Patents
Use of F-Glucoside peptide in preparing medicine for treating tumour Download PDFInfo
- Publication number
- CN101015680B CN101015680B CN2007100136586A CN200710013658A CN101015680B CN 101015680 B CN101015680 B CN 101015680B CN 2007100136586 A CN2007100136586 A CN 2007100136586A CN 200710013658 A CN200710013658 A CN 200710013658A CN 101015680 B CN101015680 B CN 101015680B
- Authority
- CN
- China
- Prior art keywords
- medicine
- treatment
- malignant tumor
- ethanol
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates to a medicine for improving immunity and treating malignant tumor and its preparation method, and belongs to the technology field of preparing medicine for treating malignant tumor. The medicine is characterized in comprising the active constituent of F-Glycocalyx which is the valid target of ecklonia kurome and is protein polysaccharides containing sulfate group extracted from ecklonia kurome. the preparation method of F-Glycocalyx comprise (1) selecting, (2) soaking and cleaning, (3) pulverizing, (4) extracting with water, (5) precipitating with alcohol of low concentration, (6) precipitating with alcohol of high concentration, and (7) purifying to obtain purified product, drying, and packaging. The inventive medicine can effectively inhibit malignant tumor viral,improve immunity with no toxicity and adverse side effect, no untoward reaction and low cost.
Description
One, technical field
The present invention relates to the application of F-glycosides peptide in the medicine of preparation treatment malignant tumor, belong to treatment malignant tumor medicine technical field.
Two, background technology
Owing to immunity of organisms reduces the malignant tumor that causes is a kind of high slight illness and the high disease of mortality rate.At present, the malignant tumor prevalence in China every year is soaring year by year, and every day is countless because of the dead patient of malignant tumor, has all brought very big misery for patient and household thereof, and the whole world prevents and treats malignant tumor, and the situation is tense.The treatment of malignant tumor, still there is not at present the medicine that can cure in the world, the medicine that now is used for the treatment of mostly is chemicals greatly, though can relief of symptoms, prolong the course of disease, but still there are a lot of problems: can not thoroughly remove the body inner virus, the drug withdrawal bounce-back easily produces untoward reaction, and side effect is big and medical expense is expensive, make the application of these medicines be very limited, thus low toxicity, effective and cheap conventional medicament particularly Chinese medicine enjoy domestic and international attention.
Three, summary of the invention
The object of the invention is to solve the weak point that prior art exists, and a kind of effectively human body immunity improving power is provided, and takes for a long time to have no side effect, can not cause untoward reaction, and cheap, to human body immunity improving power, the treatment malignant tumor has medicine of obvious curative effects and preparation method thereof.
Modern medicinal Sargassum reaches over one hundred kind, has that heat-clearing and toxic substances removing, inducing diuresis to remove edema, the kidney invigorating nourish heart, effects such as activating blood circulation to dissipate blood stasis and the anthelmintic that helps digestion.Contain plurality of active ingredients in the Sargassum, the F-glycosides peptide that wherein extracts from Sargassum has good effects such as raising immunity antitumor, and the clinical research result shows that F-glycosides peptide has the good curing effect to multiple malignant tumor.
The medicine of a kind of human body immunity improving power of the present invention, treatment malignant tumor, its effective ingredient that comprises is a F-glycosides peptide;
F-glycosides peptide is the effective site of single medicinal material Thallus Laminariae (Thallus Eckloniae), is the protein polysaccharide of a kind of sulfur acid ester group of extracting from the single medicinal material Thallus Laminariae (Thallus Eckloniae), and full name is a sulfonic acid fucoside polypeptide polymer;
The main physicochemical characteristics of F-glycosides peptide is: soluble in water, and dissolubility 〉=30%, white or yellow polycrystal powder, the fragrance that tool is special; SO
4 2-Content is 20 ± 5%, and fucose content is 20 ± 5%, and protein content is 10-18%.
The preparation method of the medicine of a kind of human body immunity improving power of the present invention, treatment malignant tumor, special character is that its F-glycosides peptide production extraction process may further comprise the steps:
1, selects materials: the high-quality limnetic dry kelp; The main place of production, Yantai, Shandong, marine site, Weihai;
2, immersion and cleaning: immersion and cleaning under the room temperature, immersion and cleaning time 30-50 minute controlled in strictness;
3, pulverize; 25-35mm width rectangular;
4, water is carried; Boiled for three times 1-1.5 hour, the 5-10 that each water yield is a Thallus Laminariae (Thallus Eckloniae) doubly;
5, low concentration precipitate with ethanol; The ethanol final concentration is 25-40%, centrifugal filtration;
6, high concentration precipitate with ethanol obtains thick product; The ethanol final concentration is 80-90%, centrifugal filtration;
7, purification obtains purified product, dry packing.
F-glycosides peptide medicine can be made into a kind of in tablet, pill, injection and the capsule;
In above-mentioned 4, it is to boil 1-1.5 hour for three times that water is carried, each water yield be Thallus Laminariae (Thallus Eckloniae) 5-10 doubly;
In 5, the low concentration precipitate with ethanol is 25-40% for the ethanol final concentration, centrifugal filtration;
In 6, the high concentration precipitate with ethanol is 80-90% for the ethanol final concentration, centrifugal filtration.
The preparation method of the medicine of a kind of human body immunity improving power of the present invention, treatment malignant tumor, mild condition is not destroyed various natural nutrient components contained in the Thallus Laminariae (Thallus Eckloniae) frond, simple to operate, improve the Thallus Laminariae (Thallus Eckloniae) comprehensive utilization degree, productive rate higher (2%), cost is lower, is applicable to suitability for industrialized production.
The medicine of a kind of human body immunity improving power of the present invention, treatment malignant tumor can be made into tablet, pill, injection and capsule (soft, hard), and every dose contains effective composition 500mg, or it is oral to follow the doctor's advice.
The using method of the medicine of a kind of human body immunity improving power of the present invention, treatment malignant tumor, every day, consumption 3000mg-6000mg can divide to give for three times, each 1000mg-2000mg.
The present invention has realized independent application F-glycosides peptide in the treatment of malignant tumor, and composition is simple, belongs to Chinese medicine, natural drug, effective human body immunity improving power is taken for a long time and is had no side effect, and can not cause untoward reaction, and cheap, malignant tumor is had obvious curative effects;
The medicine of a kind of human body immunity improving power of the present invention, treatment malignant tumor can effectively be contained malignant tumor virus, improves body immunity, takes for a long time to have no side effect, and can not cause untoward reaction, and cheap, and malignant tumor is had obvious curative effects.
Four, the specific embodiment
Describe the present invention in detail with embodiment below, but these embodiment must not be interpreted as the limitation of the present invention that goes up in all senses.
Embodiment 1:
The medicine of a kind of human body immunity improving power, treatment malignant tumor, its effective ingredient that comprises is a F-glycosides peptide, F-glycosides peptide is the effective site of single medicinal material Thallus Laminariae (Thallus Eckloniae), it is the protein polysaccharide of a kind of sulfur acid ester group of from the single medicinal material Thallus Laminariae (Thallus Eckloniae), extracting, its main physicochemical characteristics is: soluble in water, dissolubility 〉=30%, white or yellow polycrystal powder, the fragrance that tool is special; SO
4 2-Content is 20 ± 5%, and fucose content is 20 ± 5%, and protein content is 10-18%.
The preparation method of medicine, its F-glycosides peptide production extraction process may further comprise the steps: the 100kg Sargassum, through soaking, clean, pulverizing, add water 800kg, 90-100 ℃ extracts 3.5h 3 times.Get the supernatant concentrating under reduced pressure to 25L, precipitate under 30% ethanol condition, get supernatant again, reduction vaporization is to 10L, adds in the ethanol of 85L95%, filter thick product.60 ℃ of dryings, purification, 100 orders are pulverized.
Embodiment 2:
The medicine of treatment malignant tumor, its clinical data and application process are as follows:
(1), case is selected
189 routine patients all meet following condition, and (1) confirms through pathology or histocytology diagnosis.(2) time-to-live＞3 month are estimated in activity situation scoring (Karnofsky) 〉=60 minute.(3) illness such as no severe cardiac, liver, kidney, hemogram, hepatic and renal function are in normal range.(4) I ~ IV phase gastric cancer, pulmonary carcinoma, the esophageal carcinoma.
(2), grouping
Before treatment, adopt the envelope method to be divided into treatment group and matched group at random respectively 189 routine patients by different parts.Treatment group (chemotherapy+F-glycosides peptide) 96 examples (wherein not patient with operation 33 examples), wherein pulmonary carcinoma 35 examples, gastric cancer 30 examples, the esophageal carcinoma 31 examples.Matched group (simple chemotherapy or radiotherapy) 93 examples (wherein not patient with operation 27 examples), wherein pulmonary carcinoma 33 examples, gastric cancer 30 examples, the esophageal carcinoma 30 examples.Two groups of clinical datas compare there was no significant difference (P＞0.05), see Table 1
Table 1
| Pulmonary carcinoma (example) | Gastric cancer (example) | The esophageal carcinoma (example) | Add up to | |
| The treatment group | 35 | 30 | 31 | 96 |
| Matched group | 35 | 30 | 30 | 93 |
Two groups of cases are all carried out conventional therapy, and pulmonary carcinoma adds the cisplatin scheme with nvelbine, and gastric cancer adopts the MF scheme, and the esophageal carcinoma adopts the linear accelerator external exposure.The treatment group begins to take the each 1000mg of F-glycosides peptide, every day 3 times simultaneously from chemicotherapy.Every month one course of treatment, totally 2 courses of treatment.Matched group is the each 150mg of chemicotherapy oral batilol of while, every day 3 times.
(3), efficacy assessment standard:
In conjunction with clinical practice, formulate following four indices synthetic determination curative effect according to " new drug (Chinese medicine) clinical research guideline ":
First: the solid tumor clinical efficacy standard of formulating according to World Health Organization (WHO) reaches CR or PR;
Second: clinical card Hou Xianzhu improves (integrated value descends 〉=3/2);
Third: test rating hemogram (WBC HB PBC) or immune indexes NK, IL-2, CD
+/ CD
8 +) stablize or have and improve (〉=3/1)
Fourth: Karnofsky scoring increases 〉=10 fens;
Above-mentioned first is up to standard to be produce effects; Three of above-mentioned second, third, fourth are up to standard to be produce effects;
Above-mentioned second, third or second, fourth is up to standard is effective;
(4), therapeutic outcome
Total effects F-glycosides peptide total effects is 87.5%, and each curative effect of dividing into groups sees the following form.
Table 2 clinical trial total effects
| Produce effects | Effectively | Invalid | Add up to | Effective percentage | |
| The treatment group | 16 | 68 | 12 | 96 | 87.5％ |
| Matched group | 6 | 33 | 54 | 93 | 41.9％ |
Treatment group and matched group be U=5.58 relatively, P＜0.01
The grouping curative effect
Table 3 esophageal carcinoma clinical trial curative effect
| Produce effects | Effectively | Invalid | Add up to | Effective percentage | |
| The treatment group | 6 | 21 | 4 | 31 | 87.0％ |
| Matched group | 2 | 11 | 17 | 30 | 43.3％ |
Treatment group and matched group be U=3.14 relatively, P＜0.01
Table 4 gastric cancer clinical trial curative effect
| Produce effects | Effectively | Invalid | Add up to | Effective percentage | |
| The treatment group | 6 | 21 | 3 | 30 | 90.0％ |
| Matched group | 2 | 10 | 18 | 30 | 40.0％ |
Treatment group and matched group be U=3.49 relatively, P＜0.01
Table 5 pulmonary carcinoma clinical trial curative effect
| Produce effects | Effectively | Invalid | Add up to | Effective percentage | |
| The treatment group | 4 | 26 | 5 | 35 | 85.7％ |
| Matched group | 2 | 12 | 19 | 33 | 42.4％ |
Treatment group and matched group be U=3.07 relatively, P＜0.01
State of an illness curative effect
Table 6 tumor situation of change
| CR(％) | PR(％) | SD(％) | PD(％) | Add up to | |
| The treatment group | 12(36.4) | 17(51.5) | 4(12.1) | 33 | |
| Matched group | 2(7.4) | 18(66.7) | 7(25.9) | 27 |
Table 7 doing well,improving situation
| The example number | Effectively | Effective percentage (%) | ||
| Tired power * * inappetence * * nausea and vomiting * * dry mouth and throat * * spontaneous sweating * * pain * | Treatment group treatment of control group group treatment of control group group treatment of control group group treatment of control group group treatment of control group group matched group | 96 93 96 93 96 93 96 93 96 93 96 93 | 78 47 69 31 24 19 55 53 51 27 25 20 | 81.3 50.5 71.9 33.3 25.0 20.4 57.3 35.3 53.1 29.0 26.0 21.5 |
* treatment group and matched group compare P＜0.05
* treatment group and matched group be P＜0.01 relatively
Treatment group and matched group comparison clinical symptoms have clear improvement.
Table 8 treatment back quality of life change situation
| Improve | Stable | Worsen | Add up to | |
| The treatment group | 12 | 79 | 5 | 96 |
| Matched group | 7 | 65 | 21 | 93 |
Treatment group and matched group be P＜0.05 relatively, and quality of life has clear improvement.
Immunologic function index situation of change before and after the treatment:
Immunologic function changes situation before and after table 9 treatment
| Improve | Stable | Descend | Add up to | |
| The treatment group | 19 | 31 | 25 | 75 |
| Matched group | 12 | 26 | 55 | 93 |
Treatment group and matched group be P＜0.05 relatively, and immunologic function is significantly improved.
Learn by statistics and handle IL-2, CD
4 +, CD
4 +/ CD
8 +Relatively there were significant differences (P＜0.05～0.01) for treatment group and matched group, illustrates that its immunologic function is significantly improved.
Untoward reaction is observed: tangible untoward reaction is not found in inspections such as the treatment heart, liver, renal function.
Sum up
F-glycosides peptide proves through clinical experimental study, cooperates patient's change, radiotherapy, can effectively treat multiple malignant tumor, improves immunity, improves patient's quality of life, does not find tangible untoward reaction.
Claims (3)
1.F-the application of glycosides peptide in the medicine of preparation treatment gastric cancer, the esophageal carcinoma.
2. according to the described application of claim 1, it is characterized in that described medicine makes a kind of in tablet, pill, injection and the capsule.
3. according to the described application of claim 1, it is characterized in that wherein F-glycosides peptide is to produce by the method that may further comprise the steps:
(1), selects materials: the high-quality limnetic dry kelp;
(2), soak and clean: room temperature soaks down and cleans, and soaks and time 30-50 minute of cleaning;
(3), be ground into the rectangular of 25-35mm width;
(4), water carries: 90-100 ℃ of extraction 3 times, 3.5h, the 5-10 that each water yield is a Thallus Laminariae (Thallus Eckloniae) is doubly;
(5), low concentration precipitate with ethanol: the ethanol final concentration is 25-40%, centrifugal filtration;
(6), high concentration precipitate with ethanol: the ethanol final concentration is 95%, and centrifugal filtration obtains thick product;
(7), purification, obtain purified product, dry packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100136586A CN101015680B (en) | 2007-03-03 | 2007-03-03 | Use of F-Glucoside peptide in preparing medicine for treating tumour |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100136586A CN101015680B (en) | 2007-03-03 | 2007-03-03 | Use of F-Glucoside peptide in preparing medicine for treating tumour |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101015680A CN101015680A (en) | 2007-08-15 |
| CN101015680B true CN101015680B (en) | 2010-11-10 |
Family
ID=38725010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100136586A Expired - Fee Related CN101015680B (en) | 2007-03-03 | 2007-03-03 | Use of F-Glucoside peptide in preparing medicine for treating tumour |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101015680B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106632717A (en) * | 2016-12-27 | 2017-05-10 | 郭宏昌 | Laminarin cationic derivative as well as preparation method and application thereof |
-
2007
- 2007-03-03 CN CN2007100136586A patent/CN101015680B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101015680A (en) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258563B (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| CN102145158B (en) | Ginger and clove composition, preparation method of ginger and clove composition and use of ginger and clove composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy | |
| CN103571704A (en) | Preparation method of agilawood health-care wine and agilawood wine thereof | |
| CN103861079A (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN101015680B (en) | Use of F-Glucoside peptide in preparing medicine for treating tumour | |
| CN103330781B (en) | There is the Chinese medicine composition of antitumor action and the preparation method of injection thereof | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN101007056B (en) | An antitumor medicinal composition and its preparation method | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| CN100584317C (en) | Traditional Chinese medicine compound preparation for preventing gastric cancer metastasis and preparation method thereof | |
| CN108635560A (en) | A kind of Chinese medicine and preparation method thereof for treating lymthoma | |
| CN110420320A (en) | A kind of Chinese medicine composition for removing gout pathogenesis basis | |
| CN101015681A (en) | Medicine for treating chronic renal failure and its preparing process | |
| CN103263475A (en) | Traditional chinese medicine composition | |
| CN1289104C (en) | Anticancer medicine and its preparation | |
| CN114949022B (en) | Traditional Chinese medicine composition for treating tumors | |
| CN103550516B (en) | A kind of preparation method for the treatment of the medicament of perianal abscess | |
| CN102727834B (en) | Traditional Chinese medicine composition for treating migraine, and preparation method and application thereof | |
| CN102133383B (en) | Ginger and fingered citron composition, preparation method thereof and application of ginger and fingered citron composition in preparation of attenuated synergistic medicaments in cancer radiotherapy and chemotherapy | |
| CN116251133B (en) | Pharmaceutical composition and traditional Chinese medicine preparation for treating rheumatism and rheumatoid diseases by using sialon bone | |
| CN107362296B (en) | Medicine for treating benign tumor of skin and preparation method thereof | |
| CN104161791A (en) | Traditional Chinese medicine composition for treating cervical and lumbar spondylosis as well as preparation method and application thereof | |
| CN105770250B (en) | Traditional Chinese medicine composition for preventing and treating lung cancer and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101110 Termination date: 20150303 |
|
| EXPY | Termination of patent right or utility model |